Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.57 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972356 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL17976623 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1374872 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL23425431 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL20444711 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL16359926 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1639395 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL23679991 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL22883381 | 0.87 | HINT1 (0.61) | HINT1STING1NT5EGSK3ARPS6KA3 | |
| SCHEMBL24247659 | 0.86 | HINT1 (0.63) | HINT1STING1NT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047617-A1 | Nucleic acid nanocarrier drug, preparation method, pharmaceutical composition and use thereof | BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD (CN) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047617-A1 | Nucleic acid nanocarrier drug, preparation method, pharmaceutical composition and use thereof | SNRPA, PABPC1, POLN | HINT1 598/4885STING1 233/4885NT5E 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.